AusCann buys a research and development facility in Perth

Company News

by Rachael Jones

Medical cannabis company AusCann Group Holdings (ASX:AC8) has bought a research and development facility in Perth in WA.

The facility will focus on AusCann’s cannabinoid pharmaceutical product pipeline, supporting development of both innovative formulations and dose forms.

AusCann Executive Director and interim CEO Dr Paul MacLeman says it allows the creation of a fully integrated, state of the art facility for medicinal cannabis.

Shares in AusCann Group Holdings (ASX:AC8) are trading 1.57 per cent higher at $0.65.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.